Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $42.59 USD
Change Today -2.25 / -5.02%
Volume 390.8K
CEMP On Other Exchanges
As of 10:19 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

cempra inc (CEMP) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/24/15 - $46.99
52 Week Low
08/1/14 - $9.12
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CEMPRA INC (CEMP)

cempra inc (CEMP) Related Businessweek News

No Related Businessweek News Found

cempra inc (CEMP) Details

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. Its lead product candidates include solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community acquired bacterial pneumonia, as well as for uncomplicated bacterial urethritis; and Taksta (CEM-102), an antibiotic that has completed Phase II clinical trials for refractory bone and joint infections. The company also produces novel macrolides for non-antibiotic uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.

55 Employees
Last Reported Date: 02/26/15
Founded in 2005

cempra inc (CEMP) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $475.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $325.0K
Chief Commercialization Officer and Executive...
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2014.

cempra inc (CEMP) Key Developments

Cempra, Inc. to Report Q2, 2015 Results on Jul 29, 2015

Cempra, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Jul 29, 2015

Cempra, Inc., Q2 2015 Earnings Call, Jul 29, 2015

Cempra, Inc., Q2 2015 Earnings Call, Jul 29, 2015

Cempra, Inc. Enters into Loan and Security Agreement with Comerica Bank

On July 10, 2015, Cempra, Inc. entered into a Loan and Security agreement with Comerica Bank. The company immediately used proceeds from the Loan and Security agreement to terminate and pay off all of the approximately $17.7 million in principal and accrued interest under the loan and security agreement by and among and Hercules Technology Growth Capital, Inc., dated as of December 20, 2011, as amended. The loan and security agreement provides that the company may borrow up to $20.0 million in a term loan and, upon FDA approval of the planned New Drug Application, or NDA, for solithromycin, the company may also borrow an aggregate amount equal to the lesser of up to 75% of the eligible inventory and 80% of eligible accounts receivable or $10.0 million (the Revolver). After FDA approval of the planned NDA for solithromycin, the company may convert the Term Loan to the Revolver, in which event the Revolver would have a maximum amount available of $25.0 million. The Loan and Security Agreement specifies the criteria for determining eligible inventory and eligible accounts receivable and ongoing limitations and conditions precedent to the ability to borrow under the Revolver. At closing, the company received the full $20 million under the Term Loan and paid a facility fee of $100,000 for the Term Loan and a facility fee of $187,500 for the Revolver. Amounts borrowed under the Term Loan may be repaid and reborrowed at any time without penalty or premium. The Term Loan will be interest-only through April 30, 2016, followed by an amortization period of 36 months of equal monthly payments of principal plus interest, beginning on May 1, 2016 and continuing on the same day of each month thereafter until paid in full. Any amounts borrowed under the Term Loan will bear interest at a floating interest rate equal to the 30 Day LIBOR rate plus 5.2%. Amounts available to be borrowed under the Revolver may also be repaid and reborrowed at any time without penalty or premium prior to December 31, 2017, at which time all advances under the Revolver shall be immediately due and payable in full. Any amounts borrowed under the Revolver will bear interest at the 30 Day LIBOR rate plus 4.2%. Once available, the Revolver is subject to an annual unused facility fee equal of 0.25%.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CEMP:US $42.59 USD -2.25

CEMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CEMP.
View Industry Companies

Industry Analysis


Industry Average

Valuation CEMP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 74.1x
Price/Book 10.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 67.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEMPRA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at